Eton Q2 product sales up 40% YoY to $9.1M; ET-400 NDA accepted with Feb 2025 PDUFA

Eton Pharmaceuticals, Inc.

2024-Q2 EPS reported -$0.15 revenue$17,040,000

Product sales and royalty revenue $9.1M, up 40% YoY and 14% sequentially; 14th straight quarter of sequential growth.
Net loss of $2.9M ($0.11/share) including $2.0M ET-400 filing fee; prior year net income $4.6M included $5.5M royalty sale.
ALKINDI SPRINKLE revenue grew 63% YoY; Carglumic Acid sales continue to exceed expectations.
NDA for ET-400 (hydrocortisone oral solution) accepted with PDUFA date Feb 28, 2025; launch quantities planned Q4 2024.
Cash $17.7M; generated $1.3M operating cash flow in Q2; expects positive cash flow for remainder of 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.